1.66

5.06% 0.08

Protalix BioTherapeutics Inc. (PLX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Protalix BioTherapeutics Inc. stock is traded at $1.66, with a volume of 690.09K. It is up +5.06% in the last 24 hours and up +5.06% over the past month. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Previous Close:

$1.58

Open:

$1.58

24h Volume:

690.09K

Relative Volume:

0.85

Market Cap:

$132.36M

Revenue:

$63.63M

Net Income/Loss:

$10.62M

P/E Ratio:

33.20

EPS:

0.05

Net Cash Flow:

$-8.64M

1W Performance:

+12.16%

1M Performance:

+5.06%

6M Performance:

-30.54%

1Y Performance:

+76.88%

1-Day Range:

$1.57

$1.66

1-Week Range:

$1.465

$1.66

52-Week Range:

$0.89

$3.10

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name

Protalix BioTherapeutics Inc.

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

972 4 988 9488

Address

2 Snunit Street, Science Park PO Box 455, Karmiel

Employee

190

Twitter

@Protalix_Bio

Next Earnings Date

2025-03-17

Latest SEC Filings

PLX's Discussions on Twitter

Compare PLX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLX Protalix BioTherapeutics Inc.	1.66	122.79M	63.63M	10.62M	-8.64M	0.05
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
Apr-17-17	Reiterated	Rodman & Renshaw	Buy
Apr-04-16	Initiated	Rodman & Renshaw	Buy
Apr-23-15	Upgrade	Jefferies	Hold → Buy
Nov-12-14	Reiterated	R. F. Lafferty	Buy
Jan-24-14	Initiated	R. F. Lafferty	Buy
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold
May-02-12	Reiterated	Oppenheimer	Outperform
Apr-30-12	Downgrade	Auriga	Buy → Hold
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy
Nov-09-10	Reiterated	Oppenheimer	Outperform
Oct-14-10	Reiterated	UBS	Buy
Dec-02-09	Reiterated	Hapoalim	Outperform
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform
Dec-01-08	Reiterated	Oppenheimer	Outperform
Mar-11-08	Initiated	UBS	Buy
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform

View All

Protalix BioTherapeutics Inc. Stock (PLX) Latest News

Aug 18, 2025

Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances - MSN

Aug 18, 2025

Aug 17, 2025

Using data tools to time your Protalix BioTherapeutics Inc. exit2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser

Aug 17, 2025

Forecasting Protalix BioTherapeutics Inc. price range with options dataJuly 2025 Analyst Calls & Verified Stock Trade Ideas - Newser

Aug 17, 2025

How Protalix BioTherapeutics Inc. stock reacts to Fed policy changesSell Signal & Growth Focused Entry Reports - Newser

Aug 17, 2025

Can machine learning forecast Protalix BioTherapeutics Inc. recoveryTrade Exit Summary & Long Hold Capital Preservation Tips - Newser

Aug 17, 2025

Why Protalix BioTherapeutics Inc. stock attracts strong analyst attentionMarket Sentiment Summary & Reliable Entry Point Alerts - Newser

Aug 17, 2025

Aug 16, 2025

Key metrics from Protalix BioTherapeutics Inc.’s quarterly dataMarket Volume Report & Free Community Consensus Stock Picks - Newser

Aug 16, 2025

What analysts say about Protalix BioTherapeutics Inc. stockJuly 2025 Price Swings & Advanced Swing Trade Entry Alerts - sundaytimes.kr

Aug 16, 2025

Can Protalix BioTherapeutics Inc. deliver consistent EPS growthDividend Hike & Free Reliable Trade Execution Plans - thegnnews.com

Aug 16, 2025

What’s the recovery path for long term holders of Protalix BioTherapeutics Inc.Market Growth Review & Community Consensus Trade Signals - Newser

Aug 16, 2025

Protalix BioTherapeutics Experiences Strong Revenue Growth, Strategic Partnerships Drive Success - AInvest

Aug 16, 2025

Aug 15, 2025

Protalix BioTherapeutics Announces Q2 2025 Results, New CFO to Take Over. - AInvest

Aug 15, 2025

PLX: New CFO to Take the Reins - Yahoo Finance

Aug 15, 2025

When is the best time to exit Protalix BioTherapeutics Inc.IPO Watch & Technical Entry and Exit Tips - Newser

Aug 15, 2025

The Psychology of Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: Understanding Market Sentiment - investchronicle.com

Aug 15, 2025

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 15, 2025